A prospective, randomized, controlled for the efficacy and safety of improving left ventricular remodeling in combined use of sacubitril-valsartan and dapagliflozin compared to RAAS inhibitors in very elderly patients with acute myocardial infarction at the early stage of hospitalization
Latest Information Update: 03 Dec 2020
At a glance
- Drugs Dapagliflozin (Primary) ; Sacubitril/valsartan (Primary) ; ACE inhibitors; Angiotensin receptor antagonists
- Indications Myocardial infarction
- Focus Therapeutic Use
- 03 Dec 2020 New trial record